Turn Therapeutics (TTRX) Other Operating Expenses (2025 - 2026)
Turn Therapeutics' quarterly Other Operating Expenses came in at -$286126.0 in Q1 2026, down 153.36% year-on-year from $536182.4 in Q1 2025, and down 153.36% quarter-over-quarter from -$112931.0 in Q1 2025.
Turn Therapeutics has reported Other Operating Expenses for 2 years, with the latest figure at -$286126.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Operating Expenses fell 153.36% year-over-year to -$286126.0; the trailing twelve-month figure through Mar 2026 stood at -$399057.0 (changed N/A YoY), and the FY2025 full-year result was -$928562.0, down 190.02% from the prior year.
- Other Operating Expenses for Q1 2026 stood at -$286126.0, down from -$112931.0 in the prior quarter.
- The five-year high for Other Operating Expenses was -$112931.0 in Q1 2025, with the low at -$286126.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Turn Therapeutics | 188.06 Mn | 188.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -286,126.00 |
| Mar 31, 2025 | -112,931.00 |